The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | A Phase Ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myeloma
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses efficacy and safety results from a Phase Ib study (NCT02513186) of novel drug combinations in multiple myeloma (MM). Bortezomib (V) and dexamethasone (d) with either cyclophosphamide (C) or lenalidomide (R) are widely used regimens in MM. Having shown potentiation when combined with bortezomib, isatuximab, a CD38 monoclonal antibody, was used in combination with VCd or VRd in 44 newly-diagnosed MM patients ineligible for transplant. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
